Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Impairment of intangible assets | — | 58,710 |
| Inventory obsolescence charge | 485 | 11,681 |
| Income tax expense | 7,617 | 3,381 |
| Depreciation and amortization expense | 732 | 3,300 |
| Non-cash lease expense | 240 | — |
| Non-cash interest expense | 342 | 1,352 |
| Fair value adjustment related to warrant and CVR liability | 5,440 | (4,127) |
| Accretion on investments | (1,219) | (1,060) |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s D&A?
- Zevra Therapeutics, Inc. (ZVRA) reported D&A of $364K in Q2 2026.
- How has Zevra Therapeutics, Inc.'s D&A changed year-over-year?
- Zevra Therapeutics, Inc.'s D&A decreased by 78.0% year-over-year, from $1.65M to $364K.
- What is the long-term trend for Zevra Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s D&A has grown at a 99.3% compound annual growth rate (CAGR), from $257K to $4.05M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Zevra Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude